336 related articles for article (PubMed ID: 24958847)
1. Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies.
Madireddi S; Eun SY; Lee SW; Nemčovičová I; Mehta AK; Zajonc DM; Nishi N; Niki T; Hirashima M; Croft M
J Exp Med; 2014 Jun; 211(7):1433-48. PubMed ID: 24958847
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.
Bitra A; Doukov T; Wang J; Picarda G; Benedict CA; Croft M; Zajonc DM
J Biol Chem; 2018 Jan; 293(4):1317-1329. PubMed ID: 29242193
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
[TBL] [Abstract][Full Text] [Related]
4. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
[TBL] [Abstract][Full Text] [Related]
5. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.
Zhao Y; Croft M
Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T Cell-Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9.
Madireddi S; Eun SY; Mehta AK; Birta A; Zajonc DM; Niki T; Hirashima M; Podack ER; Schreiber TH; Croft M
J Immunol; 2017 Oct; 199(8):2721-2728. PubMed ID: 28877989
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
Chester C; Sanmamed MF; Wang J; Melero I
Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
[TBL] [Abstract][Full Text] [Related]
8. Constitutive interaction between 4-1BB and 4-1BBL on murine LPS-activated bone marrow dendritic cells masks detection of 4-1BBL by TKS-1 but not 19H3 antibody.
Mbanwi AN; Lin GHY; Wang KC; Watts TH
J Immunol Methods; 2017 Nov; 450():81-89. PubMed ID: 28789924
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of cancer with 4-1BB.
Vinay DS; Kwon BS
Mol Cancer Ther; 2012 May; 11(5):1062-70. PubMed ID: 22532596
[TBL] [Abstract][Full Text] [Related]
10. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.
Qi X; Li F; Wu Y; Cheng C; Han P; Wang J; Yang X
Nat Commun; 2019 May; 10(1):2141. PubMed ID: 31105267
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
12. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
[TBL] [Abstract][Full Text] [Related]
13. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Moran AE; Kovacsovics-Bankowski M; Weinberg AD
Curr Opin Immunol; 2013 Apr; 25(2):230-7. PubMed ID: 23414607
[TBL] [Abstract][Full Text] [Related]
14. 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation.
Kim DH; Chang WS; Lee YS; Lee KA; Kim YK; Kwon BS; Kang CY
J Immunol; 2008 Feb; 180(4):2062-8. PubMed ID: 18250411
[TBL] [Abstract][Full Text] [Related]
15. Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses.
Smith SE; Hoelzinger DB; Dominguez AL; Van Snick J; Lustgarten J
Cancer Immunol Immunother; 2011 Dec; 60(12):1775-87. PubMed ID: 21789593
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
[TBL] [Abstract][Full Text] [Related]
17. CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases.
Wong HY; Schwarz H
J Autoimmun; 2020 Aug; 112():102499. PubMed ID: 32505443
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
[TBL] [Abstract][Full Text] [Related]
19. CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.
Zapata JM; Perez-Chacon G; Carr-Baena P; Martinez-Forero I; Azpilikueta A; Otano I; Melero I
Front Immunol; 2018; 9():2618. PubMed ID: 30524423
[TBL] [Abstract][Full Text] [Related]
20. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
